1. Market Research
  2. > Pharmaceutical Market Trends
  3. > Contract Manufacturing in Pharmaceutical Industry, 2015 - 2025

Contract Manufacturing in Pharmaceutical Industry, 2015 - 2025

  • February 2015
  • -
  • Roots Analysis Private Ltd.
  • -
  • 319 pages

INTRODUCTION
Amongst the increasing financial pressures and the need to reduce cost and improve efficiencies, the pharmaceutical industry has witnessed a paradigm shift from vertically integrated business model to a network of suppliers. As such, contract manufacturing has evolved as one of the integral components of the pharmaceutical market. Started initially as a one-off activity, contract manufacturing has evolved into a dynamic business model; currently most prevalent in manufacturing, outsourcing is steadily spanning the entire pharmaceutical value chain. With CMOs now offering the entire multitude of services from design and discovery to final packaging, the concept of ‘one stop shop’ service provider is gradually gaining pace.

The market has witnessed several major trends that have governed the evolution of contract manufacturing over the past few years. One of the most significant changes in the outsourcing space is the emergence of strategic contract manufacturing. The conventional model of contract manufacturing involved a vendor-customer equation. However, phasing out that traditional concept, contract manufacturers nowadays believe in entering in strategic alliances with CMO partners with the objective of cutting down production cost and enhancing product pipelines.

The contract manufacturing market, broadly categorized into API manufacturing and FDF manufacturing, has witnessed significant growth in the past several years driven by factors such as cost efficiency, technical expertise, and increased time efficiency. The current marketplace is inundated with numerous established as well as emerging CMOs, with a diverse array of service offerings and scale of operation. Despite being faced with challenges such as heavy competition and lack of funding, contract manufacturing in itself characterizes a huge opportunity for the pharmaceutical sector. Inevitably, substantial growth prospects lie ahead for pharmaceutical contract manufacturers; CMOs who will be able to provide certain differentiating elements targeting diverse customer groups stand to benefit the most in this competitive landscape.

SCOPE OF THE REPORT
The ‘Contract Manufacturing in Pharmaceutical Industry, 2015 - 2025’ report provides an extensive study of the rapidly growing pharmaceutical contract manufacturing market. With pharmaceutical and biotechnology industry striving to minimize costs and maximize profits, outsourcing has emerged as an ever increasing trend. The study presents an in-depth analysis of a diverse set of CMOs on some of the key parameters such as type of business operation, scale of operation, packaging form, geographical location and range of services. In addition, it captures some of the key growth areas which will likely present tremendous opportunities for CMOs and ensure an accelerated pace of growth. Some of the potential growth areas include biopharmaceutical and high potency manufacturing. Specifically, in these markets, complex manufacturing requirements and capital intensive nature of the business make outsourcing an attractive option.

The report assesses some of the key drivers that have governed the evolution of contract manufacturing market over the past several years along with an elaborate discussion on the future trends that will shape the market in the coming years. One of the focus areas of this study is to estimate size of the future opportunity in the pharmaceutical contract manufacturing market over the next decade, segmented on the basis of business operations and key regions.

In addition to some of the well-known benefits and a promising outlook, the study also highlights considerable challenges currently prevalent in the market. Examples include quality concerns, cultural differences and lack of transparency in the manufacturing process. Nevertheless, these challenges are paving the way for new strategies and technological improvements, which will indeed be advantageous in the long run.

The base year for the report is 2014; the report provides market forecasts for the period 2015 - 2025. The research, analysis and insights presented in this report is backed by a deep understanding of key insights gathered both from secondary and primary research.

EXAMPLE HIGHLIGHTS
1. North America and Europe are the predominant regions where majority of the production facilities of CMOs are located. Out of 509CMOs we studied, 189 have presence in multiple locations in the US. In Europe,the other major hub for CMOs, Germany, Italy and the UK have presence of 58, 37 and 32 CMOs respectively. Companies have also gradually moved their focus to developing countries in order to take advantage of the relatively lower costs.
2. The market is well distributed between API manufacturers and FDF manufacturers. Within FDF contract manufacturing, solid dose compounds currently dominate the market. However, future growth is likely to be driven by injectables dose manufacturing primarily due to increased focus on complex disease areas and the growing trend of self-administration.
3. In terms of analysis by scale of operation, majority of the CMOs have the capability to operate on clinical as well as commercial scale. Out of 394 CMOs evaluated for this exercise, 340 CMOs have the provision for both clinical and commercial stage manufacturing.
4. High potency and biopharmaceuticals manufacturing represent a major growth opportunity for CMOs. Owing to the capital intensive nature of the business and complex manufacturing requirements, CMOs have become the preferred manufacturing partners for majority of the pharmaceutical clients.
5. The intense competition in the marketplace is driving CMOs to explore innovation aspects such as eClinical systems, cloud based computing and risk monitoring tools to create differentiation. Specifically, for biopharmaceuticals manufacturing, CMOs have started utilizing novel bio-processing services and technologies such as single use bioreactors.
6. With respect to the market size, we have estimated the API and FDF contract manufacturing to be worth USD 35 Billion currently. Driven by the increasing trend of outsourcing, we expect the market to grow at an annualized rate of 8.3%.

RESEARCH METHODOLOGY
Most of the data presented in this report has been gathered by secondary research. We have also conducted interviews with experts in the area (academia, industry, medical practice and other associations) to solicit their opinions on emerging trends in the market. This is primarily useful for us to draw out our own opinion on how the market will shape up across different regions and drug segments. Where possible, the available data has been checked for accuracy from multiple sources of information.

The secondary sources of information include
- Annual reports
- Investor presentations
- SEC filings
- Industry databases
- News releases from company websites
- Government policy documents
- Other analysts’ opinion reports

While the focus has been on forecasting the market over the coming nine years, the report also provides our independent view on various technological and non-commercial trends emerging in the industry. This opinion is solely based on our knowledge, research and understanding of the relevant market gathered from various secondary and primary sources of information.

CHAPTER OUTLINES
Chapter 2 provides an executive summary of the insights captured in our research. The summary offers a high level view on where the pharmaceutical contract manufacturing market is headed in the mid-long term.

Chapter 3 provides the definition of contract manufacturingand a general introduction on the role of a third party service provider in the pharmaceutical industry. We have also explained, in detail, the range of services offered by CMOs and challenges involved in contract manufacturing.

Chapter 4 highlights the key growth drivers and restraints of the contract manufacturing market. The chapter also talks about various models of contract manufacturing and some of the important trends that have shaped the market in the past several years.

Chapter 5 details contract manufacturing space specifically in China and India, providing information on regulatory framework, growth drivers, challenges and emerging opportunities in each of these countries. The chapter also provides a high-level view on production capabilities of some of the leading Chinese and Indian CMOs in the market.

Chapter 6 provides a detailed analysis of a diverse set of established and emerging pharmaceutical CMOs active in the market. An in-depth review including regional distribution, analysis by type of business operation, scale of operation, packaging and services has been covered in this chapter.

Chapter 7 focuses on biopharmaceutical contract manufacturing, a major growth opportunity for CMOs. The chapter provides an in-depth analysis specifically for biopharmaceutical CMOs on some of the key parameters including geographical location, scale of operation, types of expression systems, types of biologics manufactured, types of bioreactors and fermentation capacity.

Chapter 8 presents the detailed forecast for both API and FDF contract manufacturing. Due to the uncertain nature of the market, we have presented three different growth tracks outlined as conservative, base and optimistic scenarios.

Chapter 9 includes profiles of some of the key players in the pharmaceutical contract manufacturing market. Each company profile includes information such as geographical presence, financial performance, manufacturing capabilities, investments, partnerships and future outlook.

Chapter 10 highlights some of the important trends that will likely govern the growth and evolution of contract manufacturing market in the future.

Chapter 11 is a collection of transcripts of interviews conducted during the course of this study. Examples of companies interviewed include Corden Pharma, Helsinn, CiVentiChem and Novasep.

Chapter 12 summarizes the overall report. In this chapter, we provide a recap of the key takeaways and our independent opinion based on the research and analysis described in previous chapters.

Chapter 13 is an appendix which provides tabulated data and numbers for all the figures provided in the report.

Chapter 14 is an appendix which provides a list of companies and organizations mentioned in the report.

Table Of Contents

Contract Manufacturing in Pharmaceutical Industry, 2015 - 2025
1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION
3.1. Context and Background
3.2. Contract Manufacturing: Definition
3.3. Services Performed by CMOs
3.4. Top Factors for CMO Selection
3.5. Risk Factors and Challenges in Contract Manufacturing

4. MARKET OVERVIEW
4.1. Chapter Overview
4.2. Growth Drivers
4.2.1. Divestment of Non-core Businesses
4.2.2. Efforts to Cut Production Costs
4.2.3. Technical Expertise
4.2.4. Shift Towards Emerging Markets
4.2.5. Biopharmaceuticals Contract Manufacturing

4.3. Restraints
4.3.1. Overcapacity
4.3.2. Price Pressures
4.3.3. Lack of Funding
4.3.4. Heavy Competition

4.4. Contract Manufacturing Models
4.4.1. Shift from Tactical to Strategic
4.4.2. Integrated End-to-End Business Model
4.4.3. Intimate Long-Term Alliances
4.4.4. Flexible Short-Term Partnership
4.4.5. Innovation Driven Contract Manufacturing
4.4.5.1. Cloud based Systems Gaining Importance
4.5. Trends

5. EMERGING REGIONS IN THE CMO MARKET
5.1. Chapter Overview
5.2. China
5.2.1. Regulatory Scenario in China
5.2.2. Challenges for Chinese CMO Market
5.2.3. Emerging Opportunities
5.2.4. Leading Contract Manufacturers in China
5.2.4.1. Asymchem Laboratories
5.2.4.2. Beijing Second Pharmaceutical
5.2.4.3. Chongqing Huapont Pharmaceutical
5.2.4.4. Porton Fine Chemicals
5.2.4.5. Tianjin Pharmaceutical
5.2.4.6. Venturepharm Laboratories
5.2.4.7. WuXiAppTec
5.2.4.8. ZhejianHisun Pharma
5.2.4.9. Zhejiang Huahai Pharmaceutical

5.3. India
5.3.1. Evolution of Indian Contract Manufacturing Model
5.3.2. Regulatory Scenario in India
5.3.3. Emerging Opportunities
5.3.4. Challenges for the Indian CMO Market
5.3.5. Leading Contract Manufacturers in India
5.3.5.1. Aurobindo Pharma
5.3.5.2. Divis Laboratories
5.3.5.3. Piramal Healthcare Pharma Solutions
5.3.5.4. Dr. Reddy's Laboratories
5.3.5.5. Dishman Pharma

6. COMPETITIVE LANDSCAPE
6.1. Chapter Overview
6.2. Analysis by Business Operations
6.3. Analysis by Scale of Operations
6.4. Analysis by Type of FDF
6.5. Analysis by Pharma Form Packaging
6.6. Analysis by Services
6.7. Analysis by Geography

7. BIOPHARMACEUTICAL CONTRACT MANUFACTURING
7.1. Chapter Overview
7.2. Manufacturing of Biopharmaceuticals
7.2.1. Microbial Expression Systems
7.2.1.1. Bacterial Protein Expression System
7.2.1.2. Yeast Protein Expression System
7.2.2. Mammalian Protein Expression System
7.2.3. Insect Protein Expression System
7.2.4. Plant Protein Expression System
7.3. Evolution of Biopharmaceutical Contract Manufacturing
7.4. Biopharmaceutical CMOs: Analysis by Region
7.5. Biopharmaceutical CMOs: Analysis by Scale of Operation
7.6. Biopharmaceutical CMOs: Analysis by Capability
7.6.1. Distribution by Type of Biologic Molecule
7.6.2. Distribution by Expression Systems
7.7. Biopharmaceutical CMOs: Type of Bioreactor

8. MARKET SIZE AND FORECAST
8.1. Forecast Methodology
8.2. Key Drivers
8.3. API Manufacturing Market, 2014 - 2025
8.4. FDF Contract Manufacturing Market, 2014 - 2025
8.4.1. FDF Contract Manufacturing Market: Distribution by Type, 2015, 2020 and 2025
8.5. Overall Contract Manufacturing Market, 2014 - 2025
8.6. Contract Manufacturing Market: Distribution by Regions (US, Western Europe, China, India, RoW)

9. COMPANY PROFILES
9.1. Chapter Overview
9.2. Patheon
9.2.1. Company Overview
9.2.2. Financial Performance
9.2.3. Manufacturing Capabilities
9.2.3.1. Manufacturing Locations
9.2.3.2. Technical Solutions
9.2.4. Partnerships
9.2.5. Approvals
9.2.6. Expansions
9.2.7. Future Outlook

9.3. Catalent
9.3.1. Company Overview
9.3.2. Financial Performance
9.3.3. Manufacturing Capabilities
9.3.3.1. Manufacturing Locations
9.3.3.2. Technical Solutions
9.3.4. Partnerships
9.3.5. Approvals
9.3.6. Expansions
9.3.6.1. Geographical Expansions
9.3.6.2. Capability Expansions
9.3.6.3. Capacity Expansions
9.3.7. Future Outlook

9.4. Fareva
9.4.1. Company Overview
9.4.2. Manufacturing Capabilities
9.4.2.1. Manufacturing Locations
9.4.3. Partnerships
9.4.4. Approvals
9.4.5. Expansions
9.4.5.1. Geographical Expansions
9.4.5.2. Capability Expansions
9.4.5.3. Capacity Expansions
9.4.6. Future Outlook
9.4.7. Excella GmbH, a Part of Fareva

9.5. Aenova
9.5.1. Company Overview
9.5.2. Manufacturing Capabilities
9.5.2.1. Dosage Forms
9.5.2.2. Manufacturing Locations
9.5.3. Approvals
9.5.4. Expansions
9.5.4.1. Geographic Expansions
9.5.4.2. Capability Expansions
9.5.4.3. Capacity Expansions
9.5.5. Future Outlook
9.5.6. Haupt Pharma

9.6. Lonza
9.6.1. Company Overview
9.6.2. Financial Performance
9.6.3. Manufacturing Capabilities
9.6.3.1. Manufacturing Locations
9.6.3.2. Technical Solutions
9.6.4. Partnerships
9.6.5. Expansions
9.6.5.1. Capability Expansions
9.6.5.2. Capacity Expansions
9.6.6. Future Outlook

9.7. Evonik
9.7.1. Company Overview
9.7.2. Financial Performance
9.7.3. Manufacturing Capabilities
9.7.3.1. Manufacturing Locations
9.7.4. Expansions
9.7.4.1. Geographic Expansions
9.7.4.2. Capability Expansions
9.7.4.3. Capacity Expansion
9.7.5. Future Outlook

9.8. Boehringer Ingelheim BioXcellence
9.8.1. Company Overview
9.8.2. Financial Performance
9.8.3. Manufacturing Capabilities
9.8.3.1. Manufacturing Locations
9.8.4. Partnerships
9.8.5. Expansions
9.8.5.1. Geographical Expansions
9.8.5.2. Capacity Expansions
9.8.6. Future Outlook

9.9. Aesica
9.9.1. Company Overview
9.9.2. Manufacturing Capabilities
9.9.2.1. Manufacturing Locations
9.9.2.2. Technical Solutions
9.9.3. Partnerships
9.9.4. Approvals
9.9.5. Expansions
9.9.5.1. Geographical Expansions
9.9.5.2. Capability Expansions
9.9.5.3. Capacity Expansions
9.9.6. Future Outlook

9.10. Famar
9.10.1. Company Overview
9.10.2. Manufacturing Capabilities
9.10.2.1. Manufacturing Locations
9.10.3. Partnerships
9.10.4. Expansions
9.10.4.1. Capacity Expansions
9.10.5. Future Outlook

9.11. Recipharm
9.11.1. Company Overview
9.11.2. Financial Performance
9.11.3. Manufacturing Capabilities
9.11.3.1. Manufacturing Locations
9.11.4. Partnerships
9.11.5. Approvals
9.11.6. Expansions
9.11.6.1. Geographical Expansions
9.11.6.2. Capability Expansions
9.11.6.3. Capacity Expansion
9.11.7. Future Outlook

9.12. Jubilant
9.12.1. Company Overview
9.12.2. Financial Performance
9.12.3. Manufacturing Capabilities
9.12.3.1. Manufacturing Locations
9.12.4. Partnerships
9.12.5. Future Outlook

10. FUTURE OF THE CMO MARKET
10.1. Chapter Overview
10.2. Focus on Emerging Markets
10.3. Shift Towards an Integrated Business Model
10.4. Biologics to Expand the Global CMO Market
10.5. Innovation to Drive Growth
10.6. Information Sharing and Collaboration
10.7. High Potency and Cytotoxic Drugs Manufacturing: Emerging Focus
10.8. Growing Demand to Spur Investment Activity
10.9. Case Study: Contract Manufacturing in Gene Therapy

11. INTERVIEW TRANSCRIPTS
11.1. Kevin Daley, Market Director (Pharmaceuticals), Novasep Synthesis
11.2. Roberto Margarita, Business Development Director, Corden Pharma
11.3. Allison Vavala, Senior Manager (Business Development), Helsinn
11.4. BhaskarVenepalli, President and CEO, CiVentiChem

12. CONCLUSION
12.1. Contract Manufacturing in Pharma: An Ever Increasing Trend
12.2. The Competitive Market to Witness an Accelerated Growth
12.3. Differentiation Strategy to Pave Way for Sustenance in the Market
12.4. Concluding Remarks

13. APPENDIX 1: TABULATED DATA

14. APPENDIX 2: LIST OF COMPANIES

LIST OF FIGURES
Figure 2.1 Range of Contract Manufacturing Services: Example CMOs
Figure 3.1 Roles of a Third Party Service Provider in Pharmaceutical Industry
Figure 3.2 Outsourcing across the Pharmaceutical Value Chain
Figure 3.3 CMOs: Range of Services
Figure 5.1 Chinese CMO Market: Growth Drivers
Figure 5.2 Indian CMO Market: Growth Drivers
Figure 6.1 Extent of Outsourcing in Pharmaceutical Operations
Figure 6.2 Pharmaceutical Contract Manufacturing Landscape
Figure 6.3 CMOs: Distribution by Business Operations
Figure 6.4 CMOs: Distribution by Scale of Operation
Figure 6.5 CMOs: Distribution by Type of Dosage Forms
Figure 6.6 Types of Pharmaceutical Packaging Forms
Figure 6.7 CMOs: Distribution by Packaging Form
Figure 6.8 CMOs: Regional Distribution
Figure 7.1 Types of Expression Systems
Figure 7.2 Biopharmaceutical CMOs: Geographical Location
Figure 7.3 Biopharmaceutical CMOs: Regional Distribution
Figure 7.4 Biopharmaceutical CMOs: Distribution by Scale of Operation
Figure 7.5 Biopharmaceutical CMOs: Distribution by Type of Biologic Molecule
Figure 7.6 Biopharmaceutical CMOs: Distribution by Expression Systems
Figure 7.7 Single Use Bioreactors: Advantages and Disadvantages
Figure 8.1 Extent of Outsourcing: API and FDF Manufacturing, 2014 - 2025
Figure 8.2 API Manufacturing Market, 2014 - 2025: Base Scenario (USD billion)
Figure 8.3 FDF Manufacturing Market, 2014 - 2025: Base Scenario (USD billion)
Figure 8.4 FDF Contract Manufacturing Market: Distribution by Type, 2015, 2020 and 2025
Figure 8.5 Overall Contract Manufacturing Market, 2014 - 2025: Base Scenario (USD billion)
Figure 8.6 Overall Contract Manufacturing Market, 2014 - 2025: Distribution by Regions (US, Western Europe, China, India, RoW)
Figure 9.1 Patheon: Revenues, 2009 - 2013 (USD million)
Figure 9.2 Patheon: Revenues by Business Divisions, 2013 (USD million)
Figure 9.3 Patheon: Revenue Break-up for CMO, 2013 (USD million, Percentage)
Figure 9.4 Catalent: Revenues, 2010 - 2014 (USD million)
Figure 9.5 Catalent: Revenues by Business Divisions, 2014 (USD million)
Figure 9.6 Lonza: Revenues, 2010 - 2014 (USD million)
Figure 9.7 Lonza: Revenues by Business Divisions, FY 2014 (CHF million)
Figure 9.8 Lonza: Potency Classification System
Figure 9.9 Evonik: Revenues, 2009 - 2013 (USD million)
Figure 9.10 Evonik: Revenues by Business Divisions, 2013 (EUR million)
Figure 9.11 Boehringer Ingelheim: Revenues, 2009 - 2013 (EUR million)
Figure 9.12 Boehringer Ingelheim: Revenues by Business Divisions, 2013 (EUR million)
Figure 9.13 Recipharm: Revenues, 2009 - 2013 (SEK million)
Figure 9.14 Recipharm: Revenues by Business Divisions, 2013 (SEK million)
Figure 9.15 Jubilant: Revenues by Business Divisions, FY 2014 (INR million)
Figure 10.1 Contract Manufacturing in Gene Therapy: By Capability
Figure 10.2 Contract Manufacturing in Gene Therapy: By Location
Figure 12.1 Pharmaceutical Contract Manufacturing: Key Drivers
Figure 12.2 API and FDF Contract Manufacturing Market (USD billion) Forecast: 2015, 2020 and 2025

LIST OF TABLES
Table 5.1 Asymchem Laboratories: Manufacturing Facilities
Table 5.2 Porton Fine Chemicals: Manufacturing Facilities and RandD Centers
Table 5.3 Venturepharm Laboratories: Holdings and Related Companies
Table 5.4 Dr. Reddy's Laboratories: Manufacturing Facilities
Table 5.5 Dishman Pharma: Business Units
Table 6.1 CMOs: Analysis by Business Operations
Table 6.2 CMOs: Analysis by Scale of Operation
Table 6.3 CMOs: Analysis by Type of FDF
Table 6.4 CMOs: Analysis by Packaging Forms
Table 6.5 CMOs: Range of Services
Table 7.1 Biopharmaceutical CMOs: Scale of Operation
Table 7.2 Biopharmaceutical CMOs: Type of Biologics
Table 7.3 Biopharmaceutical CMOs: Analysis by Expression Systems
Table 7.4 Biopharmaceutical CMOs: Analysis by Type of Bioreactor
Table 9.1 Patheon: Capacity for Sterile Formulations Filling
Table 9.2 Patheon: Facilities
Table 9.3 Patheon: Additional Agreements, 2012-2014
Table 9.4 Catalent: Manufacturing and Laboratory Facilities
Table 9.5 Fareva: Manufacturing and Laboratory Facilities
Table 9.6 Aenova: Manufacturing Locations
Table 9.7 Lonza: Custom Development and Custom Manufacturing Sites
Table 9.8 Evonik: Facilities Sites and their Functions
Table 9.9 BioXcellence: Facilities and their Functions
Table 9.10 Aesica: Facility Sites and their Functions
Table 9.11 Famar: Facility Sites and their Functions
Table 9.12 Recipharm: Facility sites and their Functions
Table 9.13 Jubilant: Facility sites and their functions
Table 10.1 HPAPI CMO Investments, 2006-2014
Table 10.2 Contract Manufactures in Gene Therapy
Table 13.1 Extent of Outsourcing in Pharmaceutical Operations
Table 13.2 CMOs: Analysis by Business Operation, Scale and Type of FDF
Table 13.3 CMOs: Distribution by Business Operations
Table 13.4 CMOs: Distribution by Scale of Operation
Table 13.5 CMOs: Distribution by FDF Dosage Forms
Table 13.6 CMOs: Analysis by Packaging Form
Table 13.7 CMOs: Distribution by Packaging Form
Table 13.8 CMOs: Range of Services
Table 13.9 CMOs: Regional distribution
Table 13.10 Biopharmaceutical CMOs: Regional Distribution
Table 13.11 Biopharmaceutical CMOs: Distribution by Scale of Operation
Table 13.12 Biopharmaceutical CMOs: Distribution by Type of Biologic Molecule
Table 13.13 Biopharmaceutical CMOs: Distribution by Expression Systems
Table 13.14 Biopharmaceutical CMOs: Analysis by Type of Bioreactor
Table 13.15 Extent of Outsourcing: API and FDF Manufacturing, 2014 - 2025
Table 13.16 API Manufacturing Market, 2014 - 2025: Base Scenario (USD Billion)
Table 13.17 API Manufacturing Market, 2014 - 2025: Conservative Scenario (USD Billion)
Table 13.18 API Manufacturing Market, 2014 - 2025: Optimistic Scenario (USD Billion)
Table 13.19 FDF Manufacturing Market, 2014 - 2025: Base Scenario (USD Billion)
Table 13.20 FDF Manufacturing Market, 2014 - 2025: Conservative Scenario (USD Billion)
Table 13.21 FDF Manufacturing Market, 2014 - 2025: Optimistic Scenario (USD Billion)
Table 13.22 FDF Contract Manufacturing Market: Distribution by Type, 2015, 2020 and 2025
Table 13.23 Overall Contract Manufacturing Market, 2014 - 2025: Base Scenario (USD Billion)
Table 13.24 Overall Contract Manufacturing Market, 2014 - 2025: Conservative Scenario (USD Billion)
Table 13.25 Overall Contract Manufacturing Market, 2014 - 2025: Optimistic Scenario (USD Billion)
Table 13.26 Overall Contract Manufacturing Market, 2014 - 2025: Distribution by Regions (US, Western Europe, China, India, RoW)
Table 13.27 Patheon: Revenues, 2009 - 2013 (USD million)
Table 13.28 Patheon: Revenues by Business Divisions, 2013 (USD million)
Table 13.29 Patheon: CMO Revenue Distribution, 2013 (USD million)
Table 13.30 Catalent: Revenues, 2010-2013 (USD million)
Table 13.31 Catalent: Revenues by Business Divisions, 2014 (USD million)
Table 13.32 Lonza: Revenues, 2010 - 2014 (CHF million)
Table 13.33 Lonza: Revenues by Business Divisions, 2013 (CHF million)
Table 13.34 Evonik: Revenues, 2009 - 2013 (EUR million)
Table 13.35 Evonik: Revenues by Business Divisions, 2013 (EUR million)
Table 13.36 Boehringer Ingelheim: Revenues, 2009 - 2013 (EUR million)
Table 13.37 Boehringer Ingelheim: Revenues by Business Divisions, 2013 (EUR million)
Table 13.38 Recipharm: Revenues, 2009 - 2013 (SEK million)
Table 13.39 Recipharm: Revenues by Business Divisions, 2013 (SEK million)
Table 13.40 Jubilant: Revenues by Business Divisions, 2013 (INR million)
Table 13.41 Contract Manufacturing in Gene Therapy: By Capability
Table 13.42 Contract Manufacturing in Gene Therapy: By Location
?
The following companies have been mentioned in this report:

1. 3M Drug Delivery Systems
2. 3P Biopharmaceuticals
3. A and Z Pharmaceutical
4. AAIPharma Services
5. Aarti CRAMS (division of Aarti Industries)
6. Aarti Drugs
7. AbbVie
8. ABL, Inc.
9. Accra Pac
10. Accucaps Industries
11. Acino AG
12. AcsDobfar Spa
13. AdAlta
14. Adamas Pharmaceuticals
15. Adhesives Research
16. Aegerion
17. Aenova
18. AERAS
19. Aesica Pharmaceuticals Limited
20. Affinity Life Sciences, Inc.
21. Afton Scientific Corporation
22. Agennix
23. Agno Pharma
24. Ajinomoto Althea
25. Akorn India Private Limited (Subsidiary of Akorn)
26. Akums Drugs and Pharmaceutical Ltd.
27. Aland (Jiangsu) Nutraceutical Co., Ltd.
28. Aldevron
29. Alkermes
30. All Chem Laboratories
31. Allergy Laboratories
32. Almac Pharma
33. Alpax Pharmaceuticals
34. Alphora Research
35. Alps Pharmaceutical
36. Amanta Healthcare
37. Amatsi
38. Ambiopharm
39. Amdipharm
40. American Antibiotics
41. American Peptide Company
42. Ami Drugs and Speciality Chemicals
43. Amoli Organics
44. Ampac Fine Chemicals
45. AMRI Inc.
46. AMW GmbH
47. AMYRA Biotech
48. Angelini Pharmaceuticals (ACRAF)
49. Anhui Biochem United Pharmaceutical Co., Ltd.
50. Ankur Drugs and Pharma Ltd.
51. AnqiuLu'an Pharmaceutical
52. Apexigen
53. API Polpharma
54. Apicore Pharmaceuticals (Subsidiary of Apicore US LLC)
55. Apiscent Labs
56. APL Sweden
57. Apotex Fermentation
58. Aptuit
59. Arbro Pharmaceuticals
60. Arch Pharmalabs
61. Arevipharma GmbH
62. Arvincare
63. Asahi Glass Company, Ltd.
64. Asahi Kasei Finechem
65. Aspen Bad Oldesloe GmbH
66. Astimex Pharma
67. AstraZeneca
68. Asymchem Laboratories
69. Athera Biotechnologies
70. Atra Pharmaceuticals Ltd.
71. Aurobindo Pharma
72. AustarPharma
73. Austin Pharma(Subsidiary of Cerilliant Corporation)
74. AutekBio, Inc.
75. Avalanche Biotechnologies
76. Avid Bioservices, Inc.
77. Avra Laboratories
78. Avyukt Pharmaceuticals
79. B. Braun Medical
80. Bachem
81. Banner Pharmacaps
82. Batavia Bioservices
83. Bausch and Lomb Incorporated
84. Bavarian Nordic GmbH
85. Baxil Pharma Ltd.
86. Baxter BioPharma Solutions
87. BCN Peptides SA
88. BeiGene Co., Ltd.
89. Beijing second Pharmaceutical Co., Ltd.
90. Belcher Pharmaceuticals, LLC
91. Beltapharm SPA
92. Ben Venue Laboratories (Subsidiary of Boehringer Ingelheim)
93. Beximco Pharmaceuticals Ltd.
94. Bharat Biotech
95. BIBITEC GmbH
96. Binex Co. Ltd.
97. Bio Elpida
98. BioferS.p.A
99. Biomay AG
100. BIOMEVA GmbH
101. Bionorica SE
102. Bio-Pharm, Inc.
103. Biopharmaceutical Development Program - Frederick National Laboratory for Cancer Research (FNLCR)
104. BioReliance
105. BioSynergy
106. Biotechpharma UAB
107. Biotika
108. Biovectra Inc
109. Biovian Ltd.
110. BioVolutions
111. BioWa, Inc.
112. Bluepharma
113. Boehringer Ingelheim BioXcellence
114. Bristol-Myers Squibb
115. Broad Pharmaceutical Co., Ltd.
116. C and O Pharmaceutical technology Limited (Subsidiary of Shionogi and Co., Ltd)
117. Cadila Pharmaceuticals Limited
118. Calyx Chemicals and Pharmaceuticals Limited
119. Cambrex
120. Capsugel
121. Catalent
122. Celladon
123. Celonic AG
124. Cenexi
125. Centaur Pharmaceuticals
126. Center for Biocatalysis and Bioprocessing, The University of Iowa
127. Century Pharmaceuticals Limited
128. Cerbios Pharma
129. Cevec Pharmaceuticals
130. CF Pharma Ltd.
131. Chartwell Pharmaceuticals llc
132. ChemCon GmbH
133. ChemPacific Corporation
134. ChemPartner
135. Cherokee Pharmaceuticals LLC
136. ChifengArker Pharmaceutical Technology Co. Ltd.
137. China Chemical and Pharmaceutical Co., Ltd.
138. Chiral Biosciences Ltd.
139. Chongqing Huapont Pharmaceutical
140. Chunghwa Chemical Synthesis and Biotech Co., Ltd.
141. Cingulate Therapeutics
142. CironPharma
143. Cispharma Inc.
144. CiVentiChem, LLC
145. CMC Biologics
146. CMIC CMO ASHIKAGA Co., Ltd.
147. Coating Place Inc
148. Cobra Biologics
149. Cody Laboratories (Subsidiary of Lannett Company)
150. Cognate BioServices
151. Coldstream Laboratories, Inc.
152. Concord Biotech Limited
153. Confab Laboratories Inc.
154. Contract Coating Inc.
155. Contract Pharmacal Corporation
156. Cook Pharmica LLC
157. Cooper Pharma Ltd.
158. Corden Pharma
159. CoreRx Inc
160. Corium International, Inc.
161. Corvette Pharmaceutical Services Group
162. Cris Pharma
163. Crown Laboratories
164. Crucell
165. CTC Bio
166. CTC Clinical Trial Consultants AB
167. CTX Lifesciences Private Limited
168. Custom Pharmaceutical Services (CPS), Dr. Reddy's Laboratories
169. Cytovance Biologics, Inc.
170. Daiichi Fine Chemical Co., Ltd.
171. Daito Pharmaceutical Co.,Ltd.
172. Dalton Pharma Services
173. Delavau LLC
174. Delmar Chemicals Inc.
175. Delpharm
176. Dental Technologies, Inc.
177. Development Center for Biotechnology, Taiwan
178. Dipharma Francis S.r.l.
179. Dishman Contract Researchand Manufacturing Services (CRAMS)
180. Divi's Laboratories Limited
181. DM Bio (Dong-A meiji)
182. Dottikon Exclusive Synthesis AG
183. Douglas Manufacturing Limited
184. Dow Corning Corporation
185. DPT Laboratories, Ltd.
186. DPx Holdings
187. DSM Pharmaceutical Products
188. DuoCort
189. Dupen Laboratories Pvt. Ltd.
190. Dwarkesh Pharmaceuticals Pvt. Ltd.
191. Ei Inc.
192. EirGen Pharma Ltd
193. Elan plc
194. Eli Lilly
195. Elite Laboratories, Inc.
196. Embio Limited
197. Emcure Pharmaceuticals
198. Emergent Biosolutions
199. Enaltec Labs
200. Encap Drug Delivery
201. Enrich pharma
202. Epic Pharma, LLC
203. Eriochem S.A.
204. ErregierreSpA
205. EsteveQuimica
206. Ethypharm
207. Euro Vital Pharma GmbH and Co. KG
208. Eurogentec Biologics
209. Euticals
210. Evonik Industries
211. Excella GmbH
212. Excelvision
213. Exela Pharma Sciences
214. F.I.S. FabbricaItalianaSintetici
215. Famar
216. Famy Care Limited
217. Fareva
218. Farmabios
219. Farmaka.s
220. Farmhispania, S.A.
221. Fermic
222. Fermion Oy
223. Ferndale Laboratories (Part of Ferndale Pharma Group)
224. Fertin Pharma A/S
225. Finecure Pharmaceuticals Ltd.
226. Flamel Technologies
227. Flamingo Pharmaceuticals
228. FlammaS.p.A.
229. Fleming Laboratories Limited
230. Florida Biologix®
231. Fluid Energy Processing and Equipment Co
232. Fresenius Kabi
233. Fujifilm Diosynth Biotechnologies
234. Fujimoto Chemicals Co., Ltd. Kinraku Plant
235. Fujirebio Europe B.V. (previously Innogenetics)
236. Future Pak LTD.
237. GandW Laboratories
238. Gallus BioPharmaceuticals
239. Genmab A/S
240. Gland Pharma Limited
241. Glatt GmbH
242. GlaxoSmithKline Biopharmaceuticals
243. Glenmark Pharmaceuticals Limited
244. Global Harvest Pharma
245. Glochem Industries Limited
246. Glycotope Group
247. Goodwin Biotechnology, Inc.
248. Gordon Laboratories, Inc.
249. GP Pharm
250. Grand River Aseptic Manufacturing Inc.
251. Granules Omnichem JV
252. Grindeks
253. Groupe PARIMA Inc.
254. Guangzhou Baiyunshan Pharmaceutical Co., Ltd.
255. Guardian Drug Company
256. Hainan Poly Pharm
257. Halo Pharmaceutical Inc
258. Hanford Pharmaceuticals
259. Hangzhou Hysen Pharma Co., Ltd.
260. Hangzhou Imaginechem
261. Haupt Pharma
262. Health Biotech Limited
263. Healthy Life Pharma Pvt. Ltd.
264. Helios Pharma
265. Helsinn Advanced Synthesis SA
266. Hetero Drugs Limited
267. Hikal Limited
268. HolopackVerpackungstechnik GmbH
269. HonsonPharmatech group, Ltd.
270. Hospira One 2 One
271. Hovione
272. Hritik Chemical Pvt. Ltd.
273. Hubei Biocause Pharmaceutical Co., Ltd
274. HUIYU Pharmaceutical
275. Hyglos GmbH
276. ICROM S.p.A.
277. IDT Australia Limited
278. IDT Biologika GmbH
279. IGI Labs, Inc.
280. IMMUNE Pharmaceutical
281. ImmuneMed, IncEclipse
282. Immunetep
283. Ind Swift Laboratories Limited
284. Indena
285. Index Ventures LLP
286. Indoco Remedies Limited
287. INFA Group
288. Inno Biologics Sdn. Bhd.
289. InnovaCaptab
290. Innovent Biologics, Inc.
291. Intas Pharmaceuticals
292. IRIX Manufacturing Inc.
293. Irvine Pharmaceutical Services
294. Isochem (Subsidiary of Aurelius AG)
295. Isofol Medical
296. J.B. Chemicals and Pharmaceuticals Ltd.
297. JohnsonandJohnson
298. Jubilant Life Sciences
299. KBI BioPharma, Inc.
300. Kekule Pharma Limited
301. Kemwell Biopharma Private Limited
302. Kilitch Drugs Ltd.
303. Kongo Chemical Co., Ltd. Head Plant
304. Korten
305. Krebs Biochemicalsand Industries Ltd
306. Laurus Labs
307. Legochem Biosciences
308. LFB Biomanufacturing
309. Lipogen
310. LOBA FeinchemieGmbh
311. Logos pharma
312. Long Pharmaceuticals, LLC
313. Lonza
314. LSNE
315. LTS LohmannTherapie-Systeme AG
316. Luitpold Pharmaceuticals, Inc.
317. Lusomedicamenta
318. Lyne Laboratories, Inc.
319. Lyra Laboratories
320. Mabion
321. Macfarlan Smith Limited
322. Macleods Pharmaceuticals Limited, Baddi
323. Madras Pharmaceuticals
324. MakcurLaboratoies Ltd.
325. Malladi Drugs and Pharmaceuticals Limited
326. Mass Biologics
327. McGuff Pharmaceuticals Inc.
328. MDC Pharmaceuticals Ltd.
329. Medicago
330. Medical Products Laboratories, Inc.
331. Medichem S.A.
332. Mediwin Pharmaceuticals
333. Menadiona, S.L.
334. Mercator Pharmaceutical Solutions
335. Merchand Co.
336. Meridian Life Science, Inc.
337. Meridian Medicare Ltd.
338. Mesoblast Limited
339. Metrics Inc.
340. MetrochemApi Private Limited
341. Micro Labs Limited
342. Microchem SRL
343. Micro-Macinazione SA
344. Micron technologies
345. Micron Technologies Ltd
346. Micro-Sphere SA
347. Microtrol Sterilization Services Private Limited
348. Mikart, Inc.
349. Milda AG
350. MiltenyiBiotec
351. Minomic International Limited
352. Mipharma Spa
353. Mirror Pharmaceuticals LLC
354. Mitovie Pharma
355. Mnemosyne Pharmaceutical Inc.
356. Molecular Partners
357. MSD Chibret
358. MSN Laboratories Private Limited
359. Multi Pack Solutions
360. Mycenax
361. Mylan Laboratories
362. Nakoda Chemicals Limited
363. Nanjing Pharmatechs Co., Ltd.
364. Nascent Biologics
365. Natco Pharma ltd.
366. Nectar Lifesciences Limited
367. Neos Therapeutics, LP
368. Nephron Pharmaceuticals Corporation
369. NerPharMaS.r.l.
370. Neuland Laboratories Limited
371. Nexgen Pharma, Inc.
372. Nextar
373. Ningbo Renjian Pharmaceutical Group
374. Niota Pharmaceuticals, Inc.
375. Nippon Rika Co., Ltd.
376. Nipro Patch Co., Ltd.
377. Nitin Lifesciences Ltd.
378. Nivon Specialities
379. Norac Pharma
380. Normaco
381. North Star Processing, LLC.
382. Norwegian Institute of Public Health
383. Norwich Pharmaceuticals Inc.
384. Novartis
385. Novasep
386. Novel Laboratories, Inc.
387. Novozyme
388. Nutragen Pharma Private Limited
389. Oakwood Laboratories, L.L.C.
390. Oasis Laboratories Pvt. Ltd.
391. Olainfarm
392. Olon, SpA
393. Oman Pharmaceutical Products Co. LLC.
394. Omega Pharma
395. Omnia Biologics
396. OncoMed Pharmaceutical
397. Oncotec Pharma Produktion GmbH
398. Orchid Pharma
399. OrexigenTherpeutics, Inc
400. OrganicoFeinchemie GmbH Wolfen
401. Orient Pharma
402. Orion Corporation
403. Orofino Pharmaceutical Group
404. OSO Bio Pharmaceuticals Manufacturing, LLC
405. Oxford BioTherapeutics
406. PacificGMP
407. Panacea Biotec Limited
408. Par Pharmaceutical Inc.
409. Parabolic Drugs
410. Paragon Bioservices
411. Pasteuria Bioscience
412. Patheon (unit of DPx Holdings)
413. PCAS Finland Oy (Subsidiary of PCAS S.A.)
414. Pegasus farmaco India Pvt. Ltd.
415. Pfanstiehl, Inc.
416. Pfizer CentreSource
417. Pharmaceutical Associates, Inc. (Subsidiary of Beach Products)
418. Pharmaceutical Manufacturing Research Services, Inc.
419. Pharmaceutics International, Inc.
420. Pharmacyclics
421. PharmAgra Labs
422. Pharmanest AB
423. Pharmasol Pharmaceuticals
424. PharmaZell
425. PharmedArtis GmbH
426. Phyton Biotech LLC
427. Piramal Pharma Solutions
428. Pisgah Labs Inc
429. Plasmid Factory
430. PolyCarbon Industries, Inc.
431. Polymun Scientific ImmunbiologischeForschung GmbH
432. Polypeptide Laboratories Inc
433. Porton Fine Chemicals Ltd.
434. Powdersize, Inc
435. PrimaPharm, Inc.
436. ProBioGen AG
437. Procaps Group
438. ProcosS.p.A.
439. Provizer Pharma
440. PureTek Corporation
441. PX' Therapeutics
442. QS Pharma LLC
443. Quality Chemical Laboratories
444. Quay Pharmaceuticals Limited
445. R L Fine Chem
446. R.p. Scherer GmbH and Co. KG
447. R5
448. Rablon
449. Radico Remedies
450. Recipharm
451. Redwig Pharma
452. Regis Technologies Inc.
453. Reliable Biopharmaceutical Corporation
454. Reliance Life Sciences
455. Reliance Life Sciences Private Limited
456. Relthy Laboratories
457. RentschlerBiotechnologie GmbH
458. Richter Helm Biologics GmbH and Co KG
459. RIVOPHARM SA
460. Roche
461. Rolabo Outsourcing, S.L.
462. Rottendorf Pharma GmbH
463. ROVI Contract Manufacturing
464. Rubicon Research Private Limited
465. Rusan
466. S.M. Pharmaceuticals
467. SAFC Inc
468. SAI Life Sciences
469. Samsung Biologics
470. Sandoz
471. Sanico N.V.
472. SanochemiaPharmazeutika AG
473. Sanofi-Aventis
474. Sanquin Pharmaceutical Servives
475. Sartorius Stedium Biotech
476. Sarvotham Care Ltd.
477. SaviorLifetec Corporation
478. SCI Pharmtech Inc.
479. Scil Proteins
480. ScinoPharm Pharmaceuticals, Ltd.
481. SellasLifeSciences Group
482. Selvok Pharmaceutical Co.
483. Sentiss Pharma
484. Shandong Xinhua Pharmaceutical Company Limited
485. Shanghai Pharmaceutical IMP. and EXP. Co., Ltd.
486. ShangPharma
487. Sharon Bio-Medicine
488. Shasun Pharmaceuticals Limited
489. Shilpa Medicare Limited
490. Siegfried
491. Sigmapharm Laboratories, LLC
492. Sirio Pharma
493. SkyePharma
494. Smruthi Organics
495. SMS Pharmaceuticals Limited
496. SocietaItalianaMedicinaliScandicci (S.I.M.S.) Srl
497. Softigel
498. Solitaire Pharmacia Pvt. Ltd.
499. Sonar Products
500. Sovereign Pharmaceuticals, LLC
501. SRS Pharmaceuticals Pvt. Ltd.
502. Stason Pharmaceuticals, Inc.
503. Statens Serum Institut
504. Sterigenics U.S., LLC
505. Suir Pharma
506. Summit Biosciences Inc
507. Sunrise Pharmaceutical Inc
508. Surya Pharmaceuticals
509. Suven Life Sciences Limited
510. Swedish orphan Biovitrum AB
511. Synbias Pharma
512. SynCo Bio Partners
513. Syncom Healthcare limited
514. Syngene (Subsidiary of Biocon)
515. Synthokem Labs Private Limited
516. Synthonics Inc
517. Tai Heng Industry Co., Ltd.
518. Taj Pharamceuticals limited
519. Tapemark Company
520. TAPI
521. Tedor Pharma Inc.
522. The Ritedose Corporation
523. Theon Pharmaceuticals
524. Therapure Biopharma Inc.
525. Tianjin Pharmaceutical
526. Time Cap Laboratories
527. Titan Pharma Pvt. Ltd.
528. Tokyo Chemical Industry Co., Ltd.
529. Tolmar
530. Torrent Pharmaceuticals Limited
531. Toyobo Biologics, Inc.
532. TygerScientificInc.
533. UCB
534. Ultratab Laboratories, Inc.
535. Ultratech India Ltd.
536. Uman Pharma Inc.
537. UMN Pharma Inc.
538. Unibiotech Formulations
539. Unichem Laboratories Limited
540. Unimark Remedies Limited
541. University of Nebraska - Biological Process Development Facility
542. UPM Pharmaceuticals
543. UQUIFA
544. US Pharma lab
545. USV Limited
546. Venturepharm Laboratories
547. Vetcare
548. Vetter Pharma
549. VGXI Inc.
550. Vibalogics
551. Viropharm
552. Vista Biologicals Corp.
553. Visum Pharmaceutical Co., Ltd.
554. Vital Health Care Pvt Ltd
555. Vivante DMP Solutions
556. VIVUS, Inc.
557. VUAB Pharma
558. Wacker Biotech GmbH
559. WaismanBiomanufacturing
560. Wanbury Limited
561. WellSpring Pharmaceutical Corp.
562. West-ward Pharmaceutical Corp (Subsidiary of Hikma PLC)
563. Wilmington PharmaTech
564. Windlas Biotech ltd.
565. Windlas Healthcare Private Limited
566. Wintac Limited
567. Wisdom Pharmaceutical Co., Ltd.
568. Wockhardt Limited
569. WRAIR Pilot Bioproduction Facility
570. WuXiAppTec Co. LTD.
571. Xcelience, LLC
572. Xellia Pharmaceuticals
573. Xian Lijun Pharmaceutical
574. Xttrium Laboratories, Inc.
575. Yaopharma Co., Ltd.
576. Yash Pharma Laboratories Pvt. Ltd.
577. Yung Zip Chemical
578. Zen Labs
579. Zenara
580. ZhejianHisun Pharma
581. Zhejian HISUN Pharmaceuticals Co.
582. Zhejiang ApeloaJiayuan Pharmaceutical Co., Ltd.
583. Zhejiang Changming Pharmaceutical Co., Ltd.
584. Zhejiang Cheng Yi Pharmaceutical Co., Ltd
585. Zhejiang Excel Pharmaceutical Co., Ltd.
586. Zhejiang Huahai Pharmaceutical
587. Zhejiang JianfengHaizhou Pharmaceutical Co. Ltd.
588. Zhejiang Jiang Yuan Tang Botechnology Co., Ltd.
589. Zhejiang Jingxin
590. Zhejiang Shenzhou Pharmaceutical Co., Ltd.
591. Zydus BSV Pharma Private Limited

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Atrial Fibrillation - Global Drug Forecast and Market Analysis to 2025

PharmaPoint: Atrial Fibrillation - Global Drug Forecast and Market Analysis to 2025

  • $ 10995
  • Industry report
  • August 2016
  • by Global Data

PharmaPoint: Atrial Fibrillation - Global Drug Forecast and Market Analysis to 2025 Summary Atrial fibrillation (AF) is the most common cardiac arrhythmia and is a heart condition that causes an irregula ...

PharmaPoint: Venous Thromboembolism - Global Drug Forecast and Market Analysis to 2025

PharmaPoint: Venous Thromboembolism - Global Drug Forecast and Market Analysis to 2025

  • $ 10995
  • Industry report
  • August 2016
  • by Global Data

PharmaPoint: Venous Thromboembolism - Global Drug Forecast and Market Analysis to 2025 Summary Venous thromboembolism (VTE) is a disease that includes a myriad of life-threatening disorders ranging from ...

Global Pharmaceutical Contract Manufacturing Organization (CMO) Market

Global Pharmaceutical Contract Manufacturing Organization (CMO) Market

  • $ 7000
  • Industry report
  • August 2016
  • by Frost & Sullivan

Emerging Business Models Drive Transformation The key objective of this research is to provide in-depth knowledge of the major global pharmaceutical CMO market segments—active pharmaceutical ingredients ...


ref:plp2015

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.